Extended surveillance to assess safety of 9-valent human papillomavirus vaccine
The safety of 9-valent HPV vaccine (9vHPV) has been established with regard to common and uncommon adverse events. However, investigation of rare and severe adverse events requires extended study periods to capture rare outcomes. This observational cohort study investigated the occurrence of three r...
Saved in:
Main Authors: | Maria E. Sundaram (Author), Burney A. Kieke (Author), Kayla E. Hanson (Author), Edward A. Belongia (Author), Eric S. Weintraub (Author), Matthew F. Daley (Author), Rulin C. Hechter (Author), Nicola P. Klein (Author), Edwin M. Lewis (Author), Allison L. Naleway (Author), Jennifer C. Nelson (Author), James G. Donahue (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
9-Valent human papillomavirus vaccine: a review of the clinical development program
by: Alain Luxembourg, et al.
Published: (2017) -
Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age
by: E. D. Moreira, et al.
Published: (2018) -
Off-Label 9-Valent Human Papillomavirus Vaccination for Actinic Keratosis: A Case Series
by: Emily Wenande, et al.
Published: (2021) -
Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
by: Suzanne M. Garland, et al.
Published: (2022) -
Post-marketing safety surveillance study of a 9-valent human papillomavirus vaccine: Comment
by: Hinpetch Daungsupawong, et al.
Published: (2024)